Seek immediate medical care if you experience the following: Severe abdominal pain or back pain Persistent vomiting Difficulty swallowing or breathing Chest pain not relieved by antacids A mass in the neck or hoarseness Excessive sweating, dizziness, or rapid heartbeat Swelling of the legs, face, or throat Decreased urine output Skin rash, hives, or itching These could signal serious conditions like pancreatitis, gallbladder issues, diabetic retinopathy, gastroparesis, kidney injury, hypoglycemia, thyroid tumor, or an allergic reaction, which are rare but serious risks of semaglutide
[] Table 1 illustrates clinical trials published in 2024-2025, as indexed in the PubMed database
However, real-life outcomes may be on the lower end
In categories like GLP-1, success will increasingly depend not just on approval, but on supply reliability, scale, and sustained patient access
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1 Trial)